EQT Life Sciences led a $44m Series B round in Cyted.

EQT Life Sciences, a European investment firm, led a $44m Series B round in Cyted, a gastrointestinal health company, with a participation from Advent Life Sciences, British Business Bank, Morningside and BGF. The financing will be used to accelerate the commercial expansion of Cyted’s diagnostics platform in the US, consolidate existing commercial success across the UK, and expand its portfolio of advanced diagnostic tests.